| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Induction of CD86, CD40, and MHC II in BALB/c B cells and CD86 and CD40 in BALB/c BMDC cells is induced by polyinosinic acid (50 µg/mL; 24 h) [1]. In a dose-dependent way, polyinosinic acid (1, 5, and 25 µg/mL; 48 h) increases [3H]thymidine absorption by BALB/c B cells [1]. BALB/c B cells and BMDC cells release IFN, while macrophages and BALB/c BMDC cells secrete TNFα and IL-12 when exposed to 50 µg/mL of polyinosinic acid for 20 hours. MHC II and CD86 are expressed more frequently in B cells of C57Bl/6, MyD88, and TLR4 mutant mice when polyinosinic acid is present [1]. C57Bl/6, MyD88, and TLR4 knockout mice's B cells' thymidine uptake is enhanced by polyinosinic acid (50 µg/mL; 48 h) [1]. A dose-dependent way is shown when IP-10 secretion is induced from BEAS-2B cells by polyinosinic acid (25 µg/mL and 50 µg/mL; 24 h)[1]. Through TRIF, polyinosinic acid (50 µg/mL; 24 h or 48 h) controls the expression of CD86 and the absorption of thymidine in B cells from TRIF+/+ and TRIF-/-mice [1]. The secretion of IFN and IFNα by TLR3+/+-derived BMDC cells was enhanced by polyinosinic acid (10, 20, or 50 µg/mL; 20 h); however, TLR3-/--derived BMDC cells were not affected [1].
|
|---|---|
| References | |
| Additional Infomation |
IMP is a purine ribonucleoside 5'-monophosphate having hypoxanthine as the nucleobase. It has a role as a human metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a purine ribonucleoside 5'-monophosphate and an inosine phosphate. It is a conjugate acid of an IMP(2-).
Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety. Inosinic acid is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Inosinic acid has been reported in Drosophila melanogaster, Arabidopsis thaliana, and other organisms with data available. Inosinic Acid is a purine ribonucleotide with hypoxanthine as the base and one phosphate group attached to the sugar moiety. Inosinic acid and its salt forms are used as flavor enhancers in industrial food production. In vivo, inosinic acid is involved in purine metabolism and acts as an intermediate in the synthesis of adenine and guanine, which are precursors for the second messenger signaling molecules adenosine monophosphate (AMP) and guanosine monophosphate (GMP), respectively. Inosinic acid is a metabolite found in or produced by Saccharomyces cerevisiae. Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety. See also: Polyinosinic acid (monomer of); Polyinosinic-Polycytidylic Acid (High MW) (monomer of); Polyinosinic-polycytidylic acid (low MW) (monomer of). |
| Molecular Formula |
348.20
|
|---|---|
| Molecular Weight |
348.20
|
| Exact Mass |
348.047
|
| CAS # |
30918-54-8
|
| Related CAS # |
30918-54-8
|
| PubChem CID |
135398640
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
2.4±0.1 g/cm3
|
| Boiling Point |
905.4±75.0 °C at 760 mmHg
|
| Flash Point |
501.4±37.1 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.918
|
| LogP |
-2.65
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
555
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O=P(O)(OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3O)O1)O)O)O
|
| InChi Key |
GRSZFWQUAKGDAV-KQYNXXCUSA-N
|
| InChi Code |
InChI=1S/C10H13N4O8P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
|
| Chemical Name |
[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8719 mL | 14.3596 mL | 28.7191 mL | |
| 5 mM | 0.5744 mL | 2.8719 mL | 5.7438 mL | |
| 10 mM | 0.2872 mL | 1.4360 mL | 2.8719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
